(New York Times) Martin Shkreli had bounced back from failure before. But over a few weeks in December 2012, it looked as if he might lose everything for good. He had $1,415. The Securities and Exchange Commission was investigating him. Investors in two hedge funds he had run were asking where their money was. The funds had about $500 in a bank account but owed investors millions of dollars. Mr. Shkreli himself owed Merrill Lynch more than $1 million. And if he could not come up with a way to keep Retrophin, his pharmaceutical company, afloat, his career and his reputation might shatter.
Jury to Decide: Were Shkreli’s Gambles to Save His Drug Company Criminal?
This entry was posted in Syndicated. Bookmark the permalink.
